Valuation: ABIONYX Pharma SA

Market Cap 71.55M 82.58M 67.52M 61.26M 115M 7.91B 116M 806M 311M 4.02B 310M 303M 12.76B P/E 2026 *
-3.71x
P/E 2027 * -6.01x
Enterprise Value 67.85M 78.31M 64.03M 58.09M 109M 7.51B 110M 765M 295M 3.81B 294M 288M 12.1B EV / Sales 2026 *
14.6x
EV / Sales 2027 * 4.82x
Free-Float
85.31%
Yield 2026 *
-
Yield 2027 * -
1 day-7.95%
1 week-8.85%
Current month-15.42%
1 month-15.76%
3 months-38.34%
6 months-47.96%
Current year-51.37%
1 week 1.64
Extreme 1.64
1.95
1 month 1.64
Extreme 1.64
2.16
Current year 1.64
Extreme 1.64
4.08
1 year 1.64
Extreme 1.64
4.26
3 years 0.95
Extreme 0.947
4.37
5 years 0.91
Extreme 0.912
4.37
10 years 0.18
Extreme 0.1766
4.37
Manager TitleAgeSince
Chief Executive Officer 49 2019-09-05
Director of Finance/CFO - -
Chief Operating Officer - 2005-12-31
Director TitleAgeSince
Director/Board Member 49 2019-09-05
Director/Board Member 52 2010-07-19
Director/Board Member 76 2015-02-05
Change 5-day change 1-year change 3-year change Capi.($)
-7.95%-8.85% - - 82.58M
+5.04%+3.66%+50.62%+103.77% 70.24B
+1.64%-0.18%+34.67%+76.81% 62.63B
-3.18%-0.78%-14.14%+369.82% 27.36B
+0.16%-0.16%+26.73%+12.12% 25.71B
+2.20%-4.72%+2.19%-13.14% 24.83B
+1.15%-1.17%+17.56%-21.92% 19.52B
-7.03%-10.19%+161.91%+303.00% 15.51B
-2.58%-3.93%-7.90%+493.42% 14.66B
+4.96%+4.63%-2.75%+864.40% 14.69B
Average -0.56%-3.28%+29.88%+243.14% 30.57B
Weighted average by Cap. +1.37%-1.85%+31.91%+168.67%

Financials

2026 *2027 *
Net sales 4.66M 5.38M 4.4M 3.99M 7.48M 515M 7.54M 52.52M 20.24M 261M 20.2M 19.75M 831M 14.77M 17.04M 13.94M 12.64M 23.72M 1.63B 23.89M 166M 64.13M 829M 64.01M 62.6M 2.63B
Net income -19.83M -22.88M -18.71M -16.97M -31.84M -2.19B -32.07M -223M -86.11M -1.11B -85.94M -84.04M -3.54B -12.92M -14.91M -12.19M -11.06M -20.75M -1.43B -20.9M -146M -56.12M -725M -56.01M -54.78M -2.31B
Net Debt -3.7M -4.27M -3.49M -3.17M -5.94M -409M -5.99M -41.7M -16.07M -208M -16.04M -15.68M -660M -400K -462K -377K -342K -642K -44.25M -647K -4.51M -1.74M -22.45M -1.73M -1.7M -71.36M
Logo ABIONYX Pharma SA
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2025, the company boasted a portfolio of 3 products in clinical development.
Employees
49
Date Price Change Volume
26-09-14 €1.668 -7.95% 27,009
26-09-11 €1.812 -2.48% 23,115
26-09-10 €1.858 -0.54% 65,872
26-09-09 €1.868 +3.43% 28,857
26-09-08 €1.806 -1.31% 9,460
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.690EUR
Average target price
10.50EUR
Spread / Average Target
+521.30%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!